#1 Clinical Trials Search in Europe

Elezanumab

Elezanumab, also known as ABT-555, is an investigational drug being studied in clinical trials for various neurological conditions. These trials aim to assess the safety and efficacy of Elezanumab in treating acute spinal cord injury, acute ischemic stroke, and multiple sclerosis. The drug is administered through intravenous infusion and is being evaluated for its potential to improve neurological function and promote neuroregeneration in patients with these challenging conditions.

Table of Contents

What is Elezanumab?

Elezanumab, also known as ABT-555, is an investigational drug currently being studied for its potential to treat various neurological conditions[1]. As an investigational drug, it has not yet been approved by regulatory agencies for widespread use, but is undergoing clinical trials to assess its safety and effectiveness[2].

What Conditions Does Elezanumab Treat?

Elezanumab is being investigated for several neurological conditions, including:

  • Acute Spinal Cord Injury (SCI): A sudden injury to the spinal cord that can lead to permanent neuromotor impairment and disability[5].
  • Acute Ischemic Stroke: A type of stroke caused by a blockage in blood flow to the brain, which can result in neurological deficits[2].
  • Multiple Sclerosis (MS): A chronic disease affecting the central nervous system, including both progressive and relapsing forms[3][4].

How Does Elezanumab Work?

Elezanumab is a monoclonal antibody, which is a type of protein designed to target specific molecules in the body. In the case of Elezanumab, it binds to and neutralizes an inhibitor of neuronal regeneration[5]. By doing so, it may potentially promote neuroregeneration, which is the regrowth or repair of nervous system tissues. This mechanism of action makes it a promising candidate for conditions involving damage to the nervous system.

How is Elezanumab Administered?

Elezanumab is administered as an intravenous (IV) infusion. This means it is given directly into the bloodstream through a vein. The frequency and duration of treatment can vary depending on the condition being treated and the specific clinical trial protocol[2][5].

Current Clinical Trials

Several clinical trials are currently underway to evaluate Elezanumab:

  • A study for acute ischemic stroke, where participants receive the drug within 24 hours of stroke onset and then every 4 weeks for 48 weeks[2].
  • Trials for both progressive and relapsing forms of Multiple Sclerosis, testing different doses of Elezanumab against a placebo[3][4].
  • A study for acute traumatic cervical spinal cord injury, administering the drug within 24 hours of injury and every 4 weeks thereafter for 48 weeks[5].

How is Elezanumab’s Effectiveness Measured?

Researchers use various scales and measures to assess the effectiveness of Elezanumab, including:

  • National Institutes of Health Stroke Scale (NIHSS): Used in stroke studies to measure the severity of stroke symptoms[2].
  • Overall Response Score (ORS): A composite score used in Multiple Sclerosis trials, derived from several functional assessments[3][4].
  • Upper Extremity Motor Score (UEMS): Used in spinal cord injury studies to assess function in the upper limbs[5].
  • Spinal Cord Independence Measures (SCIM III): Evaluates self-care abilities in spinal cord injury patients[5].

Potential Benefits of Elezanumab

While the full benefits of Elezanumab are still being investigated, the drug shows promise in several areas:

  • Potential to improve neurological function in stroke patients[2].
  • Possible reduction in disability progression in Multiple Sclerosis[3][4].
  • Potential to enhance upper limb function in spinal cord injury patients[5].

It’s important to note that as an investigational drug, the full safety profile and efficacy of Elezanumab are still being determined through ongoing clinical trials. Patients interested in this treatment should consult with their healthcare providers about the possibility of participating in clinical trials or accessing the drug through expanded access programs where available[1].

Aspect Details
Drug Name Elezanumab (ABT-555)
Administration Method Intravenous (IV) infusion
Conditions Studied Acute Spinal Cord Injury (SCI), Acute Ischemic Stroke, Multiple Sclerosis (MS) – Progressive and Relapsing forms
Trial Design Randomized, Double-Blind, Placebo-Controlled
Primary Outcomes Changes in neurological function, disability improvement, overall response scores
Assessment Tools NIHSS, mRS, EDSS, UEMS, ORS, SCIM III
Treatment Duration Typically 48-52 weeks, with doses every 4 weeks
Mechanism of Action Binds to an inhibitor of neuronal regeneration, potentially promoting neuroregeneration

FAQ

  • What is Elezanumab? Elezanumab, also known as ABT-555, is an investigational drug being studied for its potential to treat various neurological conditions. It is a monoclonal antibody that binds to an inhibitor of neuronal regeneration, potentially promoting neuroregeneration.
  • What conditions is Elezanumab being studied for? Elezanumab is being studied in clinical trials for acute spinal cord injury (SCI), acute ischemic stroke, and multiple sclerosis (MS), including both progressive and relapsing forms of MS.
  • How is Elezanumab administered? Elezanumab is administered through intravenous (IV) infusion. In the clinical trials, participants typically receive doses every 4 weeks for a specified period, often up to 48 or 52 weeks.
  • What are the main goals of the Elezanumab clinical trials? The main goals of the Elezanumab clinical trials are to evaluate the safety and efficacy of the drug in treating the targeted neurological conditions. Researchers are assessing changes in neurological function, disability improvement, and overall response scores in participants.
  • Are the Elezanumab clinical trials placebo-controlled? Yes, most of the Elezanumab clinical trials are randomized, double-blind, and placebo-controlled. This means that participants are randomly assigned to receive either Elezanumab or a placebo, and neither the participants nor the study doctors know which treatment is being given.

Ongoing Clinical Trials on Elezanumab

  • Study on the Safety and Effectiveness of Elezanumab for Adults with Acute Traumatic Cervical Spinal Cord Injury

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Elezanumab: An investigational drug, also known as ABT-555, being studied for its potential to treat neurological conditions. It is a monoclonal antibody that may promote neuroregeneration.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to specific targets in the body. In the case of Elezanumab, it binds to an inhibitor of neuronal regeneration.
  • Intravenous (IV) infusion: A method of delivering medications directly into the bloodstream through a vein using a needle or catheter.
  • Acute Spinal Cord Injury (SCI): A sudden injury to the spinal cord that can result in loss of sensation, movement, and function below the level of injury.
  • Acute Ischemic Stroke: A type of stroke caused by a blockage in blood flow to the brain, leading to damage of brain tissue.
  • Multiple Sclerosis (MS): A chronic disease affecting the central nervous system, where the immune system attacks the protective covering of nerves.
  • Progressive Multiple Sclerosis (PMS): A form of MS characterized by steady worsening of neurologic functioning, with or without relapses.
  • Relapsing Multiple Sclerosis (RMS): A form of MS characterized by clearly defined attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • Upper Extremity Motor Score (UEMS): A measure used to assess the function of key muscles in the upper limbs, particularly in spinal cord injury patients.
  • National Institutes of Health Stroke Scale (NIHSS): A systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit.
  • Modified Rankin Scale (mRS): A scale used to measure the degree of disability or dependence in daily activities of people who have suffered a stroke or other neurological disabilities.
  • Overall Response Score (ORS): A composite score used in clinical trials to assess changes in neurological function, combining measures from various tests and scales.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare with the effects of the investigational drug.

References

  1. https://clinicaltrials.gov/study/NCT04278235
  2. https://clinicaltrials.gov/study/NCT04309474
  3. https://clinicaltrials.gov/study/NCT03737812
  4. https://clinicaltrials.gov/study/NCT03737851
  5. https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-elezanumab-for-adults-with-acute-traumatic-cervical-spinal-cord-injury/